CDSCO IVD Import Registration in India

IVDs run on the same four-class scale as devices, but the criteria are diagnostic-specific: what the test detects, and what happens if it gets the answer wrong. A low-risk Class A IVD might be a general laboratory reagent, while a Class D IVD is one where a wrong result carries a serious public-health or individual risk — think tests for transmissible agents in donated blood, or tests that decide a critical treatment. The higher the consequence of a false result, the higher the class and the heavier the evidence.

This is why an experienced eye matters at the classification stage. Two kits that look similar on the shelf can sit in different classes depending on the intended use and the clinical decision they drive. We classify against CDSCO’s IVD categorisation before filing, so the application carries the right evidence for its class rather than too little (which stalls) or too much (which wastes time and money).

• Class A & B IVDs — lower risk, lighter evidence, often State-level for domestic.
• Class C & D IVDs — higher risk, central review, deeper performance evidence.
• Blood-screening and companion diagnostics typically sit at the high-risk end.

Where a device dossier leans on design and manufacturing, an IVD dossier lives or dies on performance. CDSCO wants to see analytical performance — how sensitive and specific the assay is, its limits of detection, its precision and its cross-reactivity — and, for higher-risk kits, clinical performance showing the test does its job on real patient samples. Weak or missing performance data is the single most common reason IVD applications attract queries.

We map exactly what performance evidence your class and claim require, identify any gaps in your existing validation, and present the data in the structure reviewers expect. Where the evidence needs strengthening, we flag it early rather than letting it surface as a deficiency letter three months into the review.

A recurring question with imported IVDs is whether performance shown elsewhere holds on Indian samples. For some kits it plainly does; for others — particularly tests for locally prevalent conditions or with population-dependent cut-offs — CDSCO may expect bridging or local performance evaluation before it is satisfied. Anticipating this is far cheaper than being told to generate it mid-review.

We assess up front whether your claim is likely to need Indian data, and if so we help design and coordinate the evaluation through appropriate laboratories, often alongside a test licence that brings the kits in for that very purpose. Handled together, the evaluation and the registration reinforce each other instead of running as two disconnected projects.

Reagents and kits are often temperature-sensitive, and India’s climate and logistics put real stress on the cold chain. CDSCO expects stability data that supports the shelf life and storage conditions you claim, and increasingly wants confidence that the product survives the conditions it will actually meet in Indian distribution — not just a European cold-room. A shelf-life claim that the stability data does not fully support is an easy target for a reviewer.

We make sure your stability and transport data line up with your labelled storage conditions and shelf life, and that the claim on the box is one the evidence can defend. It is the kind of consistency check that keeps an IVD application moving rather than stalling on a mismatch.

The core of the file is the Device Master File written for a diagnostic — device description, the assay principle, manufacturing, analytical and clinical performance, and the risk file — supported by the Plant Master File for the site, a Free Sale Certificate from the country of origin, ISO 13485:2016 certification, and labelling that meets the Indian requirements. For higher-risk kits, add the deeper clinical performance evidence and any Indian evaluation data.

As always with CDSCO, the files have to agree with each other and with the label. A shelf life stated one way in the stability study and another way on the carton, or a performance claim in the DMF that the data does not quite reach, is exactly what a reviewer pulls on. We cross-check the whole package before it is filed.

IVD import registrations broadly track medical-device timelines — a matter of months for lower-risk kits, longer for Class C and D where the performance evidence is scrutinised harder and Indian evaluation may be involved. The delays that hurt are IVD-specific: thin performance data, a stability claim the evidence cannot support, or a late realisation that Indian bridging data is needed. Each of these is avoidable with the right groundwork before filing.

• Lower-risk kits: a few months, subject to a clean performance file.
• Class C & D: longer, driven by performance scrutiny and any Indian evaluation.
• Front-loading performance and stability evidence is the biggest time-saver.

Not every IVD fits the standard mould, and the ones that do not are where inexperience shows. Companion diagnostics — tests that decide whether a patient should get a particular drug — sit at the high-risk end because a wrong result changes a treatment decision, and CDSCO scrutinises their clinical performance accordingly. Molecular and genetic assays raise their own questions around analytical validation, controls and the reference methods used to establish accuracy. Point-of-care devices, used outside a controlled lab by non-specialists, have to prove they still perform in untrained hands and rougher conditions.

Each of these categories carries expectations that a generic dossier approach simply misses. We have handled enough of them to know where the reviewer will press — the controls in a molecular kit, the clinical concordance for a companion diagnostic, the usability evidence for a point-of-care test — and we build those answers into the file before they are asked for. For a novel assay with no obvious predicate or comparator, we also help frame the evidence so the reviewer can actually place it, which is often half the battle with genuinely new diagnostics.